A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis.

Keywords

Infliximab, Medicine, Placebo, Rheumatoid arthritis, Internal medicine

References

• Long-term health outcomes and quality of life in American and Italian inception cohorts of patients with juvenile rheumatoid arthritis. II. Early predictors of outcome.Nicolino Ruperto, Angelo Ravelli, Joseph E. Levinson — 1997
• Evaluation of the comparative efficacy and tolerability of rofecoxib and naproxen in children and adolescents with juvenile rheumatoid arthritis: a 12-week randomized controlled clinical trial with a 52-week open-label extension.Andreas Reiff, Daniel J. Lovell, Janet van Adelsberg — 2006
• The effect of HLA-DR on susceptibility to rheumatoid arthritis is influenced by the associated lymphotoxin alpha-tumor necrosis factor haplotype.Julia L. Newton, Matthew A. Brown, Anita Milicic — 2003
• Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trialRavinder N. Maini, E. William St. Clair, Ferdinand C. Breedveld — 1999
• Long-term outcome in patients with juvenile idiopathic arthritis.Kirsten Minden, Martina Niewerth, Joachim Listing — 2002
• Juvenile rheumatoid arthritis in Rochester, Minnesota 1960-1993. Is the epidemiology changing?Lynne S. Peterson, Tom Mason, Audrey M. Nelson — 1996
• Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial.E. William St. Clair, Désirée van der Heijde, Josef S Smolen — 2004
• A randomized, double-blind clinical trial of two doses of meloxicam compared with naproxen in children with juvenile idiopathic arthritis: short- and long-term efficacy and safety results.Nicolino Ruperto, И. П. Никишина, Evgueni D. Pachanov — 2005
• A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate.Nicolino Ruperto, Kevin Murray, V. Gerloni — 2004
• Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type.Pierre Quartier, Pierre Taupin, Franck Bourdeaut — 2003
• Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: interim results from an ongoing multicenter, open-label, extended-treatment trial.Daniel J. Lovell, Edward H. Giannini, Andreas Reiff — 2003
• Preliminary definition of improvement in juvenile arthritis.Edward H. Giannini, Nicolino Ruperto, Angelo Ravelli — 1997
• Efficacy of repeated intravenous infusions of an anti-tumor necrosis factor alpha monoclonal antibody, infliximab, in persistently active, refractory juvenile idiopathic arthritis: results of an open-label prospective study.V. Gerloni, Irene Pontikaki, M. Gattinara — 2005
• Infliximab or etanercept in the treatment of children with refractory juvenile idiopathic arthritis: an open label studyPekka Lahdenne, Paula Vähäsalo, Visa Honkanen — 2003
• Measurement of health status in children with juvenile rheumatoid arthritis.Gurkirpal Singh, Balu H. Athreya, James F. Fries — 1994
• Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease.Stephen B. Hanauer, Carrie Wagner, Mohan Bala — 2004
• A study of classification criteria for a diagnosis of juvenile rheumatoid arthritis.J Cassidy, Joseph E. Levinson, Juan Bass — 1986
• The German etanercept registry for treatment of juvenile idiopathic arthritisGerd Horneff, H Schmeling, T Biedermann — 2004
• Performance of the preliminary definition of improvement in juvenile chronic arthritis patients treated with methotrexateNicolino Ruperto, Angelo Ravelli, Fernanda Falcini — 1998
• Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab.Klaus Bendtzen, Pierre Geborek, Morten Svenson — 2006

Cited by

• Tumor necrosis factor inhibitors: clinical utility in autoimmune diseases.Maria Alice V. Willrich, David Murray, Melissa R. Snyder — 2015
• Systemic Juvenile Idiopathic Arthritis.J. Barnes, N. Kapur-Dromson — 2018
• Tumor Necrosis Factor Inhibitors in the Management of Juvenile Idiopathic ArthritisSusan Shenoi, Carol A. Wallace — 2010
• The use of methotrexate in children with rheumatic diseases.Raúl Gutiérrez-Suárez, R Burgos-Vargas — 2010
• Assessment and Management of Pain in Juvenile Idiopathic ArthritisJennifer E. Weiss, Nadia Luca, Alexis Boneparth — 2014
• Rheuma bei Kindern und JugendlichenGregor Dückers, Tim Niehues — 2011
• Juvenile idiopathic arthritis: an update for the clinician.Philip Kahn — 2012
• Summary of AHRQ’s Comparative Effectiveness Review of Disease-Modifying Antirheumatic Drugs for Children with Juvenile Idiopathic ArthritisRobert McMahan, Lisa M. Balfe, Laurence Greene — 2012
• Therapie der juvenilen idiopathischen Arthritis (JIA)Klaus Tenbrock — 2012
• Safe and Effective Medicines for ChildrenMarilyn J. Field, Thomas F. Boat — 2012
• Evidenz der Therapie chronisch-entzündlicher Erkrankungen in Kindheit und Adoleszenz mit BiologikaHans‐Iko Huppertz, Hartwig Lehmann — 2014
• [Recommendations for the use of methotrexate in patients with juvenile idiopathic arthritis].Inmaculada Calvo, Jordi Antón, Juan Carlos López Robledillo — 2016
• Anti-TNF treatment in juvenile idiopathic arthritis and associated uveitis : Clinical perspectives on growth, uveitis, and drug survivalPirjo Tynjälä — 2008
• АБАТАЦЕПТ: НОВЫЕ ВОЗМОЖНОСТИ В ТЕРАПИИ ДЕТЕЙ С ПОЛИАРТИКУЛЯРНЫМ ЮВЕНИЛЬНЫМ ИДИОПАТИЧЕСКИМ АРТРИТОМArray Руперто — 2010
• Needs in paediatric Rheumatology: The PRINTO perspectiveNicolino Ruperto — 2010
• Biologic-Associated Infections in Pediatric RheumatologyGerd Horneff — 2015
• Abatacept in the treatment of polyarticular JIA: development, clinical utility, and place in therapyHashkes, Gil Goldzweig — 2011
• Ultrasonography for Diagnosis, Intervention and Follow-up in Juvenile Idiopathic ArthritisL. Laurell — 2011
• Генно-инженерная биологическая терапия ювенильного артритаХ. Михельс, И. П. Никишина, Е С Федоров — 2011
• The development and assessment of biological treatments for children.Eve Smith, Helen Foster, Michael W. Beresford — 2015

Related papers

• [Management of failure of infliximab in inflammatory bowel disease].N. Naïja, Sami Karoui, M. Serghini — 2011
• Anti-infliximab antibodies are already detectable in most patients with rheumatoid arthritis halfway through an infusioncycle: an open-label pharmacokinetic cohort studyBart J. F. van den Bemt, Alfons A den Broeder, Gertjan Wolbink — 2011
• Trough Levels and Antibodies to Infliximab May Not Predict Response to Intensification of Infliximab Therapy in Patients With Inflammatory Bowel DiseaseBenjamin Pariente, Guillaume Pineton de Chambrun, Roman Krzysiek — 2012
• Anti-infliximab antibodies in patients with rheumatoid arthritis who require higher doses of infliximab to achieve or maintain a clinical response.Boulos Haraoui, Louise P. Cameron, Michèle Ouellet — 2006
• Methotrexate alone and methotrexate combined with etanercept in treatment of rheumatoid arthritisSylejman Rexhepi, Mjellma Rexhepi, Blerta Rexhepi — 2012
• Methotrexate in resistant juvenile rheumatoid arthritis. Results of the U.S.A.-U.S.S.R. double-blind, placebo-controlled trial. The Pediatric Rheumatology Collaborative Study Group and The Cooperative Children's Study Group.Edward H. Giannini, Earl J. Brewer, N. N. Kuzmina — 1992
• Measures of health status and quality of life in juvenile rheumatoid arthritis: Pediatric Quality of Life Inventory (PedsQL) Rheumatology Module 3.0, Juvenile Arthritis Quality of Life Questionnaire (JAQQ), Paediatric Rheumatology Quality of Life Scale (PRQL), and Childhood Arthritis Health Profile (CAHP)Adam C. Carle, Esi Morgan DeWitt, Michael Seid — 2011
• 50 years ago in the Journal of Pediatrics: clinical and serologic observations in patients with juvenile rheumatoid arthritis and their relatives.Philip J. Hashkes — 2013